Definium Therapeutics (DFTX) Income towards Parent Company (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Income towards Parent Company data on file, last reported at -$58.2 billion in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 191821.42% year-over-year to -$58.2 billion in Q1 2026; TTM through Mar 2026 was -$60.9 billion, a 58428.48% decrease from a year earlier, with the FY2025 full-year figure at -$31.1 billion, down 632.56% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$58.2 billion, down from -$45.4 million in the prior quarter.
• Over the last five years, Income towards Parent Company for DFTX reached as high as -$5.1 million in Q4 2022 and fell as low as -$58.2 billion in Q1 2026.
• Historically, Income towards Parent Company has averaged -$3.6 billion across 5 years, with a median of -$22.0 million in 2024.
• Across the five-year window, Income towards Parent Company soared 62.53% in 2022 and plunged 191821.42% in 2026, its largest moves.
• Year by year, Income towards Parent Company stood at -$5.1 million in 2022, then slumped by 305.93% to -$20.8 million in 2023, then plunged by 43.37% to -$29.8 million in 2024, then plunged by 52.06% to -$45.4 million in 2025, then tumbled by 128183.18% to -$58.2 billion in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$58.2 billion in Q1 2026, -$45.4 million in Q4 2025, and -$44.7 million in Q3 2025.